Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
SCYX
#3582
SCYNEXIS, Inc.
0.7
5
+4.17%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+4.17%
Monatliche Änderung
-6.25%
6 month change
-9.64%
Jahresänderung
-25.00%
Vorheriger Schlusskurs
0.7
2
Open
0.7
5
Bid
Ask
Low
0.7
5
High
0.7
5
Volumen
3
Märkte
Aktien
Gesundheitswesen
SCYX
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
37.95 M
38.98 M
39.02 M
41.92 M
41.97 M
—
Valuation ratios
Enterprise value
27.81 M
31.12 M
30.21 M
17.27 M
17.52 M
96.11 M
Price to earnings ratio
-2.22
-2.75
-1.7
-1.69
-1.51
-7.65
Price to sales ratio
8.43
15.67
17.6
10.17
12.95
56.4
Price to cash flow ratio
11.39
2.44
1.69
1.38
1.13
6.64
Price to book ratio
0.27
1.07
0.21
0.16
0.2
1.63
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.03
0.04
0.08
0.11
0.17
0.4
Return on equity %
0.05
0.07
0.11
0.15
0.24
0.56
Return on invested capital %
117.8
124.08
132.56
316.45
504.05
1 077.13
Gross margin %
100
100
100
100
100
400
Operating margin %
1 563.64
824.16
3 350.19
700.95
2 516.47
7 391.77
EBITDA margin %
—
—
—
—
—
—
Net margin %
425.45
369.6
2 097.67
504.77
2 572.16
5 544.19
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
3.13
3
5.83
5.2
5.75
19.78
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.01
0
0.02
0.01
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
0
0
0
—
Long term debt to total equity ratio
—
—
0
0
0
—
Per share metrics
Operating cash flow per share
-0.02
0.2
0.15
0.15
0.17
0.68
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
1.75
1.55
1.09
0.93
0.76
4.33
Net current asset value per share
1.65
1.49
1.06
1.14
0.98
4.66
Tangible book value per share
1.2
1.14
1.02
0.89
0.73
3.78
Working capital per share
1.13
0.99
0.88
0.92
0.81
3.59
Book value per share
1.2
1.14
1.02
0.89
0.73
3.78
Nachrichten
SCYNEXIS doses first patients in SCY-247 IV formulation trial
JERSEY CITY - FDA grants fast track and QIDP designations to SCYNEXIS drug
Scynexis erhält 180-Tage-Fristverlängerung von der Nasdaq zur Erfüllung der Börsenanforderungen
Scynexis receives 180-day extension from Nasdaq to meet listing requirements
Forschung an Antimykotika: SCYNEXIS sichert sich jährlichen Zuschuss von 7 Millionen US-Dollar
SCYNEXIS receives $7 million annual grant for antifungal research
Guggenheim senkt Kursziel für SCYNEXIS nach GSK-Einigung auf 3 $
Guggenheim lowers SCYNEXIS stock price target to $3 after GSK trial resolution
SCYNEXIS erhält 22 Millionen US-Dollar von GSK nach Abbruch der MARIO-Studie
SCYNEXIS receives $22 million from GSK as MARIO study ends
Einigung mit GSK: Scynexis erhält 24,3 Mio. US-Dollar und stoppt MARIO-Studie
Scynexis to receive $24.3 million from GSK as MARIO study ends per new agreement